Kintara Therapeutics, Inc. (KTRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KTRA Stock Price Chart Interactive Chart >
KTRA Price/Volume Stats
| Current price | $6.30 | 52-week high | $42.00 |
| Prev. close | $6.03 | 52-week low | $3.50 |
| Day low | $5.91 | Volume | 40,828 |
| Day high | $6.74 | Avg. volume | 40,780 |
| 50-day MA | $7.43 | Dividend yield | N/A |
| 200-day MA | $8.61 | Market Cap | 10.18M |
Kintara Therapeutics, Inc. (KTRA) Company Bio
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.
Latest KTRA News From Around the Web
Below are the latest news stories about KINTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate KTRA as an investment opportunity.
Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be presenting at the Biotech Showcase Conference in San Francisco. |
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and highly-aggressive childhood brain cancer. |
10 Pump and Dump Stocks Hedge Funds LikeIn this article, we discuss the 10 pump and dump stocks hedge funds like. If you want to read about some more pump and dump stocks, go directly to 5 Pump and Dump Stocks Hedge Funds Like. The influx of retail investors on the stock market in recent months and the rise of social media […] |
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City. |
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementKintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market. |
KTRA Price Returns
| 1-mo | -8.56% |
| 3-mo | 21.62% |
| 6-mo | -42.60% |
| 1-year | -69.64% |
| 3-year | -76.47% |
| 5-year | -99.17% |
| YTD | -8.56% |
| 2022 | -72.98% |
| 2021 | -60.16% |
| 2020 | 85.59% |
| 2019 | -79.71% |
| 2018 | -68.81% |
Loading social stream, please wait...